Fig. 3From: A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocolAn example of clinical report for body composition profiling (AMRA® Profiler 4 MAsS Scan), including whole-body water-fat separated imaging examples (bottom left), the muscle assessment score (MAsS; blue region of the report) which are the biomarkers used in the primary aim to assess sarcopenia, as well as measurements of abdominal adiposity (bottom right)Back to article page